MedPath

Effects of Magnesium Oxide on Clinical Equivalence of Rosuvastati

Not Applicable
Recruiting
Conditions
hyperlipidaemia
Registration Number
JPRN-UMIN000025610
Lead Sponsor
Fukuoka University Chikushi Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Patients who is not be able to sign the consent (2)Patient that it was judged that drug management in being at home had a problem by the principal investigator or subinvestigator (3)Patients receiving drugs both aluminum and magnesium (4)Other patients judged inappropriate by the principal investigator or subinvestigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
As the primary end point, we examined the rate of change in the LDL-C level after 12 weeks in patients achieving a compliance of more than 80% based on compliance-checking sheets.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath